Subscribe
www-billionphotos-com-shutterstock-com-11
www.BillionPhotos.com / Shutterstock.com
29 February 2016Americas

Polymer patent invalidated by split Federal Circuit

The US Court of Appeals for the Federal Circuit has invalidated a polymer patent owned by Howmedica Osteonics, reversing an earlier decision from the US Patent and Trademark Office (USPTO) and ending the company’s long running dispute with medical device company Zimmer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit upholds Howmedica patent ruling
13 May 2016   The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
Federal Circuit upholds Howmedica patent ruling
13 May 2016   The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.

More on this story

Americas
Federal Circuit upholds Howmedica patent ruling
13 May 2016   The US Court of Appeals for the Federal Circuit has refused to review an earlier ruling that invalidated a patent owned by Howmedica Osteonics in the company’s dispute with medical device company Zimmer.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York